Patent · US Active

ULK1 inhibitors and methods using same

US10266549B2 · kind B2 · utility

3Cited by
5References
20Claims
0Family size

Assignees

Inventors

Key dates

Filing dateAug 25, 2015
Grant dateApr 23, 2019
Priority date—
Expiry dateAug 25, 2035

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2800/52
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.